We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avecia-Trilink Partner to Offer Scale-up in Oligonucleotide Manufacturing
News

Avecia-Trilink Partner to Offer Scale-up in Oligonucleotide Manufacturing

Avecia-Trilink Partner to Offer Scale-up in Oligonucleotide Manufacturing
News

Avecia-Trilink Partner to Offer Scale-up in Oligonucleotide Manufacturing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Avecia-Trilink Partner to Offer Scale-up in Oligonucleotide Manufacturing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avecia Biotechnology and TriLink BioTechnologies Inc. have announced an alliance to offer customers scale-up of manufacturing for the entire lifecycle of oligonucleotide-based drug discovery, development and commercialization.

By adopting common technology platforms, Avecia and TriLink are offering an integrated management and technology solution that is designed to enable customers to transition from R&D and pre-clinical studies to clinical trials and beyond.

The companies are partnering to provide customers with a unified manufacturing approach to ensure transition between the pre-clinical and clinical phases of drug development.

This alliance is designed to offer a solution for drug developers looking to minimize the challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company.

TriLink and Avecia are harmonizing their processes, so customers can enjoy a smooth changeover when scaling up for clinical trials.

"Avecia and TriLink share similar high standards for customer service and quality, so Avecia has always been our top recommendation to customers preparing to scale up," said Dr. Richard Hogrefe, CEO and President of TriLink.

"This alliance integrates our methods to give customers the most direct path from initial research to the clinic."

"We successfully transferred our technology to Trilink - now, together, we’ll be able to serve more clients in pre-clinical development and provide faster and smoother transfer into clinical development," added Detlef Rethage, President of Avecia Biotechnology Inc.

Advertisement